Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years [Phase 3]

View source ↗

Summary

A Phase 3 follow-up study (Study 208) of FSME Immun NEW in volunteers aged 16 to 66 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 3 | Status: COMPLETED